Skip to main content

Table 4 Treatment-emergent adverse events reported by at least 5% of patients treated with exenatide once weekly

From: Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

Adverse event, n (%) Overall (N = 1830)
Nausea 305 (16.7)
Diarrhea 207 (11.3)
Nasopharyngitis 152 (8.3)
Headache 145 (7.9)
Injection site nodule 141 (7.7)
Vomiting 128 (7.0)
Constipation 109 (6.0)
Injection site pruritus 101 (5.5)
  All* Severe Non-severe
Hypoglycemia 317 (17.3)   
  Background sulfonylurea use 230 (28.8) 0 (0.0) 104 (13.0)
  No background sulfonylurea use 86 (8.3) 1 (0.1) 23 (2.2)
  1. *All hypoglycemia: includes severe, non-severe, and symptoms of hypoglycemia (defined as any episode of hypoglycemia that does not meet severe or non-severe event criteria); Severe hypoglycemia: symptoms resulting in loss of consciousness or seizure that showed prompt recovery after administration of glucose, or documented blood glucose <54 mg/dL that required third-party assistance because of severe impairment in consciousness or behavior; Non-severe hypoglycemia: signs or symptoms of hypoglycemia accompanied by fingerstick blood glucose <54 mg/dL.